GlaxoSmithKline, Pfizer Shine

HER2-positive breast cancer breast cancer is a more aggressive form of the cancer caused by a genetic mutation in tumor cells. It affects 20% to 30% of breast cancer patients and has a higher likelihood or reappearing after treatment.

GlaxoSmithKline shares closed at $55.99 Friday.

While big pharma companies made headlines Saturday morning at ASCO, big biotechs like Amgen(AMGN Quote) also featured prominently.

The world's biggest biotech reported interim results from a safety and efficacy study of its experimental drug panitumumab, which was found to be effective in stopping tumor growth in patients with metastatic colorectal cancer.

According to early results, 13% of patients whose condition did not improve with standard chemotherapy saw their tumors shrink thanks to the drug, and 30% of patients' tumors stopped growing. However, as of the interim analysis, 88 patients had enrolled in the trail and only 23 patients met the criteria for evaluation. Researchers are looking to enroll at total of 150 patients in the trial.

In addition, Amgen reported results from an early trial involving its drug AMG 706 as a monotherapy for advanced thyroid cancer. The phase I trial, which was designed to determine the appropriate dosing for the drug, suggests that the drug has "promising anti-tumor activity," according to an Amgen press release. Phase I is the first stage of clinical drug trials in humans.

Amgen's shares closed at $69.18 Friday.